Idebenone (re-assessment: Leber's hereditary optic neuropathy (LHON))

Subject:

• Active Substance: Idebenone
• Name: Raxone^®
• Therapeutic area: Leber's hereditary optic neuropathy (LHON)
• Pharmaceutical company: Chiesi GmbH

Time table:

• Start: 01.04.2022
• Final decision by G-BA: 15.09.2022

Final decision:

• Hint for a non-quantifiable additional benefit